Salivary level of interleukin-8 in oral precancer and oral squamous cell carcinoma
Interleukin 8 (IL-8) is a pro-angiogenic, pro-inflammatory mediator that belongs to the family of chemokines. Due to its pro-angiogenic characteristic, it may play a vital role in tumour angiogenesis and progression.
This study was designed to estimate the levels of salivary IL-8 in oral precancer and oral squamous cell carcinoma (OSCC) patients and compare them with healthy controls. The aim was to evaluate its efficacy as a potential biomarker for these diseases.
Materials and methods
Each group comprised 25 individuals. The salivary IL-8 levels were determined by enzyme-linked immunosorbent assay.
The levels of salivary IL-8 were found to be significantly elevated in patients with OSCC as compared to the precancer group (p < 0.0001) and healthy controls (p < 0.0001). However, the difference in salivary IL-8 concentrations among the precancer group and controls was statistically non-significant (p = 0.738).
Our results suggested that salivary IL-8 can be utilised as a potential biomarker for OSCC. Salivary IL-8 was found to be non-conclusive for oral premalignancy in this preliminary study. Hence, its possible role in transition from premalignancy to malignancy needs further research with larger sample sizes.
Saliva as a diagnostic biofluid offers a number of advantages over blood-based testing. The role of IL-8 in oral cancer if validated further by future research can provide an easy diagnostic test as well as a prognostic indicator for patients undergoing treatment. Therefore, if it’s role in tumourigenesis can be sufficiently assessed, it could open up new avenues to find out novel treatment modalities for oral cancer.
KeywordsOral squamous cell carcinoma Oral precancer Saliva Interleukin-8 ELISA
Oral squamous cell carcinoma
Head and neck squamous cell carcinoma.
Oral submucous fibrosis
Moderately differentiated squamous cell carcinoma
Well-differentiated squamous cell carcinoma
- 3.Shafer WG, Levy BM, Hine MK, Rajendran R, Sivapathasundharam B (2006) Shafer’s textbook of oral pathology. Elsevier, New DelhiGoogle Scholar
- 14.Young MRI, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, Collins SL et al (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte–macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74:69–74PubMedCrossRefGoogle Scholar
- 16.Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR (1995) Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte–macrophage colony-stimulating factor. Clin Cancer Res 1:95–103PubMedGoogle Scholar
- 17.Smith CW, Chen Z, Dong G, Loukinova E, Pegram MY, Figueroa LN, Waes CV (1998) The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1 α, IL-6, GM-CSF, and KC. Clin Exp Metastasis 16:655–664PubMedCrossRefGoogle Scholar
- 25.Chaiyarit P, Ultrawichian A, Leelayuwat C, Vatanasapt P, Chcnchareonsook N, Samson MH, Giraud AS (2011) Investigation of trefoil factor expression in saliva and oral mucosal tissues of patients with oral squamous cell carcinoma. Clin Oral Investig. doi:10.1007/s00784-011-0667-z
- 29.Greenberg MS, Glick M, Ship JA (2008) Burkets oral medicine. BC Decker, OntarioGoogle Scholar
- 30.Greenberg MS, Glick M (2003) Burket’s oral medicine diagnosis and treatment. BC Decker, OntarioGoogle Scholar
- 52.SahebJamee M, Eslami M, Moghadam FA, Sarafnejad A (2008) Salivary concentration of TNFα, IL1α, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 13:292–295Google Scholar